Search research articles
Contact Us
Filters
Showing results (31-40 of 50) with videos related to
Page
of 5
Sort By:
International Urology and Nephrology
|
April 2, 2024
Adequacy of prostate cancer prevention and screening recommendations provided by an artificial intelligence-powered large language model
Giuseppe Chiarelli, Alex Stephens, Marco Finati, et al.
World Journal of Urology
|
December 26, 2024
Oncological outcomes and prognostic implications of T1 histo-anatomic substaging in the management of high-Grade non-muscle invasive bladder cancer: results from a large single centre series
Marco Finati, Antonio Fanelli, Francesco Cinelli, et al.
Clinical Genitourinary Cancer
|
September 7, 2024
The Impact of Radical Prostatectomy Versus Radiation Therapy on Cancer-Specific Mortality for Nonmetastatic Prostate Cancer: Analysis of an Other-Cause Mortality Matched Cohort
Marco Finati, Nicholas James Corsi, Alex Stephens, et al.
The Prostate
|
October 28, 2024
Association of race with incidence, characteristics, and mortality from incidental prostate cancer: Analysis of two North American contemporary cohorts
Marco Finati, Chase Morrison, Alex Stephens, et al.
Cancer
|
May 28, 2024
Race has no impact on prostate cancer-specific mortality, when comparing patients with similar risk of other-cause mortality: An analysis of a population-based cohort
Shane A Tinsley, Marco Finati, Alex Stephens, et al.
World Journal of Urology
|
March 27, 2023
Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
Gian Maria Busetto, Marco Finati, Marco Chirico, et al.
The Journal of Liquid Biopsy
|
July 23, 2025
Liquid Biopsy: Current advancements in clinical practice for bladder cancer
Felice Crocetto, Ugo Amicuzi, Michele Musone, et al.
European Urology Open Science
|
November 24, 2025
Refining Active Surveillance Eligibility in Intermediate-risk Non-muscle-invasive Bladder Cancer: The Impact of Time to First Recurrence
Marco Finati, Nicola Schiavone, Biagio Barone, et al.
International Urology and Nephrology
|
November 11, 2024
Surgery versus radiation for clinically positive nodal prostate cancer in an other cause mortality risk weighted cohort
Shane A Tinsley, Alex Stephens, Marco Finati, et al.
Journal of Clinical Medicine
|
April 26, 2025
Which Surrogate Marker of Insulin Resistance Among Those Proposed in the Literature Better Predicts the Presence of Non-Metastatic Bladder Cancer?
Giovanni Tarantino, Ciro Imbimbo, Matteo Ferro, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 50) with videos related to
Sort By:
Page
of 5
International Urology and Nephrology
|
April 2, 2024
Adequacy of prostate cancer prevention and screening recommendations provided by an artificial intelligence-powered large language model
Giuseppe Chiarelli, Alex Stephens, Marco Finati, et al.
World Journal of Urology
|
December 26, 2024
Oncological outcomes and prognostic implications of T1 histo-anatomic substaging in the management of high-Grade non-muscle invasive bladder cancer: results from a large single centre series
Marco Finati, Antonio Fanelli, Francesco Cinelli, et al.
Clinical Genitourinary Cancer
|
September 7, 2024
The Impact of Radical Prostatectomy Versus Radiation Therapy on Cancer-Specific Mortality for Nonmetastatic Prostate Cancer: Analysis of an Other-Cause Mortality Matched Cohort
Marco Finati, Nicholas James Corsi, Alex Stephens, et al.
The Prostate
|
October 28, 2024
Association of race with incidence, characteristics, and mortality from incidental prostate cancer: Analysis of two North American contemporary cohorts
Marco Finati, Chase Morrison, Alex Stephens, et al.
Cancer
|
May 28, 2024
Race has no impact on prostate cancer-specific mortality, when comparing patients with similar risk of other-cause mortality: An analysis of a population-based cohort
Shane A Tinsley, Marco Finati, Alex Stephens, et al.
World Journal of Urology
|
March 27, 2023
Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
Gian Maria Busetto, Marco Finati, Marco Chirico, et al.
The Journal of Liquid Biopsy
|
July 23, 2025
Liquid Biopsy: Current advancements in clinical practice for bladder cancer
Felice Crocetto, Ugo Amicuzi, Michele Musone, et al.
European Urology Open Science
|
November 24, 2025
Refining Active Surveillance Eligibility in Intermediate-risk Non-muscle-invasive Bladder Cancer: The Impact of Time to First Recurrence
Marco Finati, Nicola Schiavone, Biagio Barone, et al.
International Urology and Nephrology
|
November 11, 2024
Surgery versus radiation for clinically positive nodal prostate cancer in an other cause mortality risk weighted cohort
Shane A Tinsley, Alex Stephens, Marco Finati, et al.
Journal of Clinical Medicine
|
April 26, 2025
Which Surrogate Marker of Insulin Resistance Among Those Proposed in the Literature Better Predicts the Presence of Non-Metastatic Bladder Cancer?
Giovanni Tarantino, Ciro Imbimbo, Matteo Ferro, et al.
Page
of 5